This bill prohibits federal agencies from purchasing biotechnology equipment and services from companies deemed threats to national security, particularly those connected to foreign adversaries like China. Within 30 days of enactment, the President must establish a federal entity led by the Office of Management and Budget to create policies and guidance for implementing these restrictions, with regulations to be finalized within one year. The bill specifically requires evaluation of Chinese biotechnology companies BGI, MGI, and Complete Genomics, along with their subsidiaries and affiliates, to determine if they pose national security risks. The legislation includes exceptions for overseas healthcare services, authorized defense and intelligence activities, and publicly available data, and allows federal agencies to request case-by-case waivers for up to one year when necessary. Federal agencies must submit detailed reports on affected contracts and grants, estimated replacement costs, and alternative suppliers within six months of the bill's enactment.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.